Skip to content
Tirzepatide Report
Provider review

RoenRx Tirzepatide Review: Bundles, Refunds and FDA Letter

Researched & written by Alan PierceClinical Pharmacology WriterUpdated

FDA warning letter
FDA issued Roen Health, Inc. dba RoenRx a warning letter in June 2026 (False & Misleading Claims/Misbranded (Telehealth)). Read the letter on FDA’s own warning-letter database.

On this page

Published tirzepatide-inclusive FAQ bundle; current selectable offer remains unverified.

Standout details

  • Published FAQ separates tirzepatide bundle from $39 care offer
  • Clinical nonapproval exception described for the bundle

Things to consider

  • Named bundle destination returns an error; current selection unverified
  • General care and filled-prescription refund rules differ from bundle promises

RoenRx's weight-loss FAQ lists a Doctor + Tirzepatide bundle at $349 for the first month, then $449 per month. It says prescribed medication and ongoing care are included, with possible extra fees beyond standard titration. This is different from the $39 introductory care membership, which ordinarily excludes medication. Obtain the exact selected plan and dose-related total before paying.3

Keep the membership and bundle separate

The general FAQ advertises medication starting at $151 per month when purchasing a three-month supply, using semaglutide as its example. That is not a tirzepatide quote. Insurance-dependent brand-drug copay examples likewise do not establish the price for an uninsured patient or a compounded bundle.3,4

The FAQ lists a dedicated tirzepatide bundle address, but the inspected destination returns an error. The general enrollment landing shows broad weight-loss goals and account links without a selected tirzepatide plan or price. The published FAQ does not establish a currently selectable prescription quote, enrollment eligibility or an accepted payment agreement. Confirm the live offer before authorizing payment.3

The policy generally separates membership from medication, while expressly recognizing medication-inclusive Doctor + Semaglutide and Doctor + Tirzepatide programs. It permits multi-month commitments and automatically renews the selected term, whether or not services are used. Confirm the amount due now, any prepaid term and next charge; a monthly equivalent need not be an installment.5

TopicWhat to know
Introductory membership$39 first month; medication ordinarily separate
Tirzepatide bundle$349 first month, then $449; dose-related exceptions
Other medication example$151/month on three-month supply is not a tirzepatide quote
Current selectionLinked bundle error; selected offer and checkout unverified
Obtain the exact plan, quantity, initial charge and renewal agreement.3,4,5

Refund promises need a governing agreement

The bundle FAQ promises a full refund if a provider finds the patient clinically ineligible and elsewhere describes a 30-day satisfaction guarantee in that context. The general policy instead makes consultation, membership and provider-visit fees nonrefundable and filled prescription orders final. Do not treat the broad marketing promise as resolving which fees are returned at every stage. Obtain the selected nonapproval exception and retained-fee calculation in writing.3,5

Cancel before renewal through the account's Manage Membership controls. The FAQ distinguishes delaying medication shipments from pausing membership: memberships cannot currently be paused. Cancellation does not retroactively refund care or medication. A separate 36-hour provision concerns inadvertent billing after timely trial cancellation, not a universal prescription-refund window.3,5

The policy directs patients with incorrect orders to support and says replacement after a delivered shipment may incur a new charge. It does not provide an unconditional free replacement for every lost or damaged shipment. Confirm the applicable pharmacy and delivery remedy before accepting a prepaid supply.5

TopicWhat to know
NonapprovalBundle refund promise versus general fee-finality policy
CancellationBefore renewal; delaying shipment is not pausing membership
FDA letterJune 8, 2026: specific compounded-semaglutide claims
Care accountabilityBruno network named; actual clinician and pharmacy unverified
Current regulatory resolution and individual eligibility were not established.3,5,6

The FDA letter concerns specific semaglutide claims

FDA's June 8, 2026 letter to Roen Health, Inc. dba RoenRx, following a March 2026 website review, concerns misleading compounded semaglutide labeling and promotion. It says pictured RoenRx labels suggested the company was the compounder and that claims implied FDA evaluation or approval. This letter must not be generalized into a warning about every tirzepatide order or a current business-closure finding.6

A response accepted by FDA or current resolution was not established. Neither a revised website nor a certification badge independently proves the matter closed, current licensure or the quality of a particular compounded preparation.6

The policy names Bruno Health, P.A. and affiliated groups in its provider network. That does not establish the actual clinician, practice or preparing/dispensing pharmacy assigned to your order. Confirm those names and medication-specific eligibility at your physical location.5 Compounded drugs are not FDA-approved; original brand-drug trials do not prove RoenRx patient outcomes or equivalent compounded results.1,2

Further reading

whether compounded tirzepatide is still legal in 2026, Zepbound side effects, the gallbladder risk, thyroid cancer warning, tirzepatide evidence guide, Rex MD, Ondra Health, best tirzepatide providers.

Frequently asked questions

Is RoenRx tirzepatide included for $39?

No. The $39 introductory care membership ordinarily excludes medication. The FAQ separately lists a medication-inclusive tirzepatide bundle at $349 first month, then $449, with possible dose-related extra fees.

Will medical nonapproval receive a full refund?

The bundle FAQ promises a refund, while the general policy makes care and membership fees nonrefundable. Obtain the selected governing exception and exact retained amount before paying.

What does the FDA letter address?

The June 8, 2026 letter concerns misleading compounded-semaglutide labeling and promotion, including compounder identity and FDA-approval implications. Current resolution, closure or every tirzepatide order cannot be inferred from it.

References(6)

  1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, and the SURMOUNT-1 Investigators (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PMID: 35658024. Read source
  2. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Bays HE, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).. New England Journal of Medicine. PMID: 40353578. Read source
  3. RoenRx (2026). Weight-loss FAQ, membership and bundled plans. RoenRx.
  4. RoenRx (2026). Weight-loss medication page. RoenRx.
  5. RoenRx (2026). Subscription, cancellation and refund policy. RoenRx.
  6. U.S. Food and Drug Administration (2026). Roen Health, Inc. dba RoenRx warning letter, June 8, 2026. U.S. Food and Drug Administration. Read source

About the author

Alan Pierce

Clinical Pharmacology Writer

About Tirzepatide Report · How we verify prices

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.